Mycovia Pharmaceuticals Announces Presentations of its Supportive Phase 3 Clinical Study (ultraVIOLET) Evaluating the Safety and Efficacy of Oteseconazole (VT-1161) for the Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) and Susceptibility Testing Against Clinical Isolates at IDWeek 2021 Virtual Conference

Durham, N.C. – September 29, 2021 – Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced that data evaluating oteseconazole for treatment of recurrent vulvovaginal candidiasis (RVVC) will be presented at the IDWeek 2021 Virtual Conference, taking place from Sept. 29 to Oct. 3. IDWeek is the joint annual meeting of the Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, the HIV Medical Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists.

Dr. Mark G. Martens, FACOG, Vice President, Academic Affairs/Chief Academic Officer, Tower Health, will present findings on “A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Oteseconazole (VT-1161) Oral Capsules versus Fluconazole and Placebo in the Treatment of Acute Vulvovaginal Candidiasis Episodes in Subjects with Recurrent Vulvovaginal Candidiasis (ultraVIOLET).”